The genetic components of the RB:CDK:cyclin:p16 tumor suppressor pathway undergo mutational and epigenetic alterations in a wide range of human cancers and serve as critical targets for inactivation by the transforming oncoproteins of several DNA tumor viruses. Lung cancer has been a useful model system for these studies as it was the first tumor to demonstrate an important role for RB in the genesis of a common adult malignancy and was also the first human cancer to demonstrate genetic evidence for a multi-component RB:p16 tumor suppressor pathway. Lung tumorigenesis, however, is a complex disease process that requires longstanding carcinogen exposure in order to acquire somatic alterations at many distinct genetic loci. Understanding the multifunctional properties of RB to regulate cell proliferation, differentiation, and apoptosis and how they relate to the sequential accumulation of other clonal gene defects will be essential in order to understand the specific patterns of gene inactivation observed in different subtypes of lung cancer and to fulfill the promise of 'molecular target' therapeutics.
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Keywords: retinoblastoma; cyclin dependent kinase; p16INK4; p27Kip1; lung cancer; neuroendocrine A current hypothesis proposes that 100% of lung cancer samples have inactivated the RB gene pathway Dissecting the multi-step process for the molecular etiology of lung cancer has been complicated for multiple reasons. These include the lack of welldefined lung cancer susceptibility kindreds, the enormous number of chromosomal loci that undergo non-random allele loss in the development of lung cancer, the realization that lung cancer may constitute a heterogeneous collection of tumors with distinct genetic etiologies, the low specificity for in vitro growth or tumor suppression assays as a functional screening tool, and the uncertain role of hypermethylation and haploinsufficiency as reliable markers for the identification of increasing number of candidate tumor suppressor genes (Eng et al., 2000; Kaye and Kubo, 2001; Kohno and Yokota, 1999; Tomizawa et al., 1998) . In this review, we will avoid much of this controversy by focusing instead on the retinoblastoma (RB) gene and its associated upstream regulatory elements. The RB gene was the first tumor suppressor gene implicated in the etiology of lung cancer (Harbour et al., 1988; Yokota et al., 1988) and the evidence linking alterations of RB activity with human lung tumorigenesis is unequivocal. In fact, the frequency of RB pathway inactivation in lung cancer is so high , it is reasonable to propose that disruption of this pathway (through the genetic or epigenetic targeting of one of several possible gene components) is a mandatory requirement for 100% of lung cancer samples. It is important to note that inactivation of the parallel and interconnecting p14ARF/p53 axis is also essential in these RB(7) lung cells in order to bypass efficient apoptosis as reviewed elsewhere (Sherr, 2001) . The broad question of how the RB gene pathway may mediate tumor suppressor effects and how to restore RB function in tumor cells is a critical topic in cancer research and has also been the subject of many recent reviews (Harbour and Dean, 2000; Sellers and Kaelin, 1997; Sherr, 2001) . However, in the special case of lung cancer, several simpler questions may also be posed. For example, why does the RB gene undergo mutational inactivation in the genesis of small cell lung cancer while the upstream cyclin-dependent kinase (CDK) inhibitor, p16, is the preferential target for inactivation in the non-small cell lung cancer subtype? In addition, since there is substantial genetic evidence that only one component in the RB tumor suppressor gene pathway needs to be inactivated for neoplastic clonal expansion Weinberg, 1995) , a different, but related question, asks whether there are important phenotypic consequences between cells that have mutated only the RB gene and retain wildtype p16 function as compared to tumor cells that have retained a wildtype RB gene but have lost p16 function. In this paper we will briefly review some of the facts that are known about the RB gene pathway in lung cancer and some of the questions that still remain.
RB gene in lung cancer
Small cell lung cancer was an unexpected model system to help define the role of the retinoblastoma (RB) gene tumor suppressor pathway in human cancer since survivors of familial retinoblastoma were not previously known to develop lung tumors with any appreciable frequency (Eng et al., 1993) and the RB gene was initially believed to be linked only with a limited range of rare pediatric tumors. Nonetheless, shortly after the validation of the RB gene as the locus that underlies the development of both familial and sporadic retinoblastoma (Friend et al., 1986; Lee et al., 1987) , mutational inactivation of the RB gene was identified in approximately 90% of the common adult malignancy, small cell lung cancer (reviewed in (Kaye and Kubo, 2001) ). While these experiments were undertaken because of evidence showing both cytogenetic alterations (Harbour et al., 1988) and loss of heterozygosity allele loss (Yokota et al., 1987) near the 13q14 locus of the RB gene, the finding that the RB gene might also encode rate-limiting tumor suppressor activity for a common, carcinogen-driven adult malignancy was indeed surprising. In addition to detecting a high frequency of absent RB protein expression in most small cell lung tumors, a few lung tumor samples exhibited a stable, but aberrantly migrating RB protein species. In each of these cases, however, a deletion or missense mutation was localized within the RB functional 'pocket' domain and was found to have specifically inactivated the tumor suppressor activity of RB Kaye et al., 1990) . Finally, the role of RB as a tumor suppressor in lung cancer was proven by the ability of RB to suppress the growth of RB(7/7) small cell and non-small cell lung cancers in vitro and with in vivo nude mouse xenograft experiments (Kratzke et al., 1993; Ookawa et al., 1993) . The molecular analysis of lung cancer, therefore, helped define the modern view that the protean functions of the RB product can impact on normal cell cycle progression and cell differentiation within a broad range of human cell lineages. However, what does small cell lung cancer have in common with retinoblastoma and why is small cell lung cancer the only human malignancy that targets the RB gene for mutational inactivation with an extraordinarily high frequency that approaches the prevalence seen in pediatric retinoblastoma tumors? While there are no ready answers to this address this question, there are several notable biological and morphological similarities between small cell lung cancer and retinoblastoma. For example, although there still remains uncertainty about the cell of origin for small cell lung cancer (Gazdar et al., 1985) , both tumors are believed to arise from a similar progenitor neural crest origin and both tumors synthesize a variety of neuroendocrine enzymes and markers. Both tumor cell types are also known to over-express the N-myc gene in a subset of their cancers (Lee et al., 1984; Nau et al., 1986) and both exhibit the unusual and characteristic property of growing in cell culture in vitro as floating spheroid clusters of 50 -200 cells. Despite these similarities, there are other neural or neuroendocrine tumors such as pediatric neuroblastoma and adult gastrointestinal or pulmonary carcinoid tumors which are rarely associated with RB mutations (Cagle et al., 1997; Easton et al., 1998) and a meaningful link between retinoblastoma and small cell lung cancer, therefore, is absent. The question which addresses why small cell lung cancer has not been described in survivors of familial retinoblastoma can be explained more easily. In contrast to retinoblastoma which requires only the inactivation of the RB gene and, perhaps, the inactivation of a second hypothetical gene product (Gallie et al., 1995) , the epidemiology and molecular cytogenetics of lung cancer has suggested the requirement of 46 (and perhaps many more) gene alterations which is consistent with the requirement for a very prolonged latency period following carcinogen exposure to the lung (Zochbauer-Muller et al., 2002) . Survivors of familial retinoblastoma, however, do not generally survive the additional 30 -40 years due to death from an increasing incidence of second nonocular malignancies, usually from sarcomas within radiotherapy ports (Abramson et al., 2001) , and may abuse tobacco at a much lower rate than the general population. Nonetheless, some studies have suggested a 10-fold increase rate of lung cancer (and in particular small cell lung cancer) in first degree relatives of patients with familial retinoblastoma (Sanders et al., 1989) . In addition, a follow-up analysis of a large multi-center retinoblastoma registry, that had now followed 139 subjects who had survived to age 40, found an increased risk of lung cancer in this group (Kleinerman et al., 2000) and concluded that lung cancer is an established risk for retinoblastoma survivors that is independent of prior radiation therapy exposure. Therefore, it is reasonable to conclude that if enough RB heterozygotes would survive to the 4th and 5th decades, then a strong familial pattern for lung cancer would emerge.
While 90% of all small cell lung cancer samples had evidence for mutational inactivation of the RB gene, this raised the issue of how to explain the small subset of tumor samples that still expressed wildtype RB protein. Although a few of these samples did not morphologically resemble small cell lung cancer and may have been misclassified, there were several other cases that exhibited characteristic neuroendocrine phenotypes. Initially, we hypothesized that these tumors might express transforming oncoproteins from DNA tumor viruses, such as SV40 large T antigen, adenovirus E1A or human papillomavirus E7, which are known to inactivate the RB product (Weinberg, 1995) . We did not detect evidence for DNA tumor viruses in any of these samples (Shimizu et al., 1994) , however, we subsequently demonstrated that inactivation of an upstream RB regulator (CDNKN2a/INK4a/p16) selectively occurred in these RB (+/+) tumors resulting in almost 100% inactivation of the RB/p16 pathway in these tumors.
p16 gene in lung cancer
One year after the landmark discovery that the RB protein can bind to the transforming products of a class of DNA tumor viruses, a tentative model for RB function was proposed based on limited data arising largely from two observations. The first observation was the tight synchronization of RB phosphorylation status with specific stages of the cell cycle such that RB was predominantly hypophosphorylated in resting cells, in terminally differentiated cells, and in cells that were arrested before the G1/S transition into DNA synthesis (Chen et al., 1989; Decaprio et al., 1989; Mihara et al., 1989) . The second observation was the ability of the SV40 large T antigen to bind preferentially to the hypophosphorylated form of RB . This data was incorporated into a tentative model where hypophosphorylated RB represents the 'active' tumor suppressor form of RB that can tightly bind to a family of cellular proteins to prevent entry into mitosis (Cooper and Whyte, 1989; Decaprio et al., 1989) which DNA tumor viruses subsequently try to disrupt to promote viral replication. This model was subsequently confirmed by the identification of a small group of nuclear RB pocket proteins (Kaelin et al., 1991 (Kaelin et al., , 1992 that have now expanded to a disparate family of over 100 members (Morris and Dyson, 2001 ). The unifying theme of this model has been that the hyperphosphorylation of RB, triggered sequentially by activation of cdk4/6:cyclin D and cdk2: cyclins E and A complexes, induces a conformational shift that antagonizes RB binding activity to release its binding partners and to 'inactivate' RB growth suppressor activity (Figure 1) . Members of the E2F family are the best characterized RB binding partners and serve as a paradigm for a link between RB functional activity and the control of cell proliferation (reviewed in Harbour and Dean (2000) ).
The almost simultaneous description of the p16 gene as the locus conferring susceptibility familial melanoma (Kamb et al., 1994) , as a common site for homozygous deletions in tumor cell lines (Kamb et al., 1994) , and as a negative regulator for the CDK4/6 kinase (Serrano et al., 1993) which phosphorylates RB in late G1, suggested that the p16 gene could be an important target for mutations in a wide range of human cancers. The inability to detect acquired somatic mutations in primary tumors within the p16 gene, however, led to initial skepticism on the role of p16 as a valid tumor suppressor gene (Cairns et al., 1994; Spruck et al., 1994) . The identification of a remarkably tight inverse correlation between mutational inactivation of RB and the loss of p16 protein expression in lung cancer (Kelley et al., 1995a; Otterson et al., 1994; Shapiro et al., 1995) , however, predicted that the association of p16 inactivation with primary lung cancer should be as strong as the connection with RB and argued convincingly that p16 is a bona fide tumor suppressor gene . Interestingly, the difficulty in identifying acquired somatic p16 mutations in tumors resulted from the unexpected observation that the p16 gene preferentially undergoes tumor-specific epigenetic gene silencing through promoter and exon 1 hypermethylation Merlo et al., 1995; Otterson et al., 1995) . Therefore, p16 mRNA silencing through DNA hypermethylation appeared phenotypically equivalent to loss of p16 function via a p16 missense mutation or homozygous deletion. The hypermethylation, however, could be transiently reversed through the incubation of tumor cells in vitro with therapeutic demethylating agents resulting in abundant p16 protein expression (Otterson et al., 1995) . In contrast, tumor cells carrying permanent p16 gene alterations showed no response, as expected, to demethylating agents. These and other observations have, accordingly, stimulated several preclinical and clinical trials that are linked to understanding the clinical/biological relevance of replacing p16 function by either using small CDK inhibitor-like analogues (Senderowicz and Sausville, 2000) in an attempt to regulate RB function or by testing methylation or DNA chromatin altering agents that may reverse epigenetic gene silencing of candidate tumor suppressor genes such as p16 in lung cancer (Momparler and Ayoub, 2001; Weiser et al., 2001) .
RB:CDK4/6:cyclin D:p16 pathway is a little more complicated
Since p16 is a selective inhibitor for the CDK4/6:cyclin D complex and since RB is the only known substrate for CDK4/6:cyclin D, the inverse correlation between loss of RB and p16 in human cancer also predicted that p16 could not exert tumor suppressor activity in the absence of wildtype RB function. While this prediction was soon confirmed (Koh et al., 1995) , the model of p16 as an exclusive regulator of activated cyclin D may be vastly oversimplified. For example, CDK4/6:cyclin D complexes can also bind to a related p21/p27/p57 Cip/Kip family of CDK2:cyclin E inhibitors (Grimison et al., 2000; Jiang et al., 1998; Sherr and Roberts, 1999) , seemingly to both sequester inhibitory activity away from CDK2:cyclin E complexes and, perhaps, to stabilize CDK4/6:cyclin D activity (Figure 1 ). The induction of p16 protein bound to CDK4, therefore, not only directly suppresses CDK4/6:cyclin D activity but also simultaneously releases free p27Kip1 which can now transfer to form inhibitory CDK2:cyclinE:p27 complexes. Since inhibition of cyclin E activity, but not cyclin D, can induce G1 arrest of proliferating cells, the indirect suppression of CDK2:cyclin E by p27Kip1 may be the primary growth suppressor function mediated by p16 induction (Jiang et al., 1998) . In fact, the specific role for cyclin D during the G1 phase of the cell cycle is still controversial (Dowdy et al., 1993; Ezhevsky et al., 2001; Geng et al., 1999; Ho and Dowdy, 2002) . In addition, although RB is maximally phosphorylated by sequential cyclin D and cyclin E phosphorylation (Adams, 2001) and RB status has been inversely correlated only with p16 protein expression in lung cancer, the possibility still exists that the deregulated phosphorylation of another unknown cyclin E substrate(s) may also be critical for p16 tumor suppressor activity during lung tumorigenesis.
The shifting fraction of bound p16 or members of the p27Kip family also helps explain the dramatically different levels of cyclin D protein which have often been detected in subsets of lung cancer samples. In this model, RB(7/7) lung cancer samples are invariably associated with absent or reduced cyclin D1 levels due to the elevated p16 protein induction which is associated (by a still unknown mechanism) with loss of RB function. Elevated p16 in turn binds to CDK4:cyclinD complexes to disrupt a critical stabilizing effect of bound p27Kip, which can then result in the loss of steady-state cyclin D1 levels (Cheng et al., 1999; Parry et al., 1995) . Understanding the unique relationships between cell cycle regulators such as RB, p16, cyclin D1 and p27Kip, therefore, will be critical for interpreting the data from a growing literature which is focused on examining these molecules as potential prognostic factors for the management of lung cancer.
RB and neuroendocrine differentiation
The questions of why small cell lung cancer and nonsmall cell lung cancer preferentially inactivate either RB or p16, respectively, and whether RB inactivation is functionally equivalent to p16 loss still remain unanswered. While in vitro data suggests that RB plays an essential role in cell cycle progression in all higher eukaryotic cells, the association of RB loss with abnormalities in neuroendocrine function and tumorigenesis is quite striking. For example, the major defect underlying the embryonic lethality of RB null mice can be primarily localized to selected regions of ectopic cell proliferation/apoptosis within neural tissues (Jacks et al., 1992; Lee et al., 1992) . In addition, RB heterozygote mice develop unusual neuroendocrine pituitary tumors and medullary thyroid cancers and the cooperative effect of breeding RB(+/7) mice with a p53 (+/7) or (7/7) genotype results in a remarkable spectrum of neuroendocrine tumors including islet cell tumors of the pancreas, adrenal pheochromocytomas, medullary thyroid cancer, and pituitary tumors which resembles a mixture of both familial multiple endocrine neoplasia (MEN)-1 and MEN-2 syndromes (Coxon et al., 1998; Harvey et al., 1995; Williams et al., 1994) . Murine knockout models targeting related CDK:cyclinD:p16 components are also disproportionately associated with end organ phenotypes that can be linked with alterations of the murine CNS hypothalamic-pituitary axis or alterations of neuroendocrine pancreatic islet cell function (reviewed in Ortega et al. 2002) ). There is to date, however, no working model that links the RB gene pathway with functional properties of the Menin (MEN 1 syndrome) or Ret (MEN 2 syndrome) gene products and an explanation to link the genetics of the RB(+/7) murine model with human neuroendocrine cancers, therefore, is still lacking.
Absence of Ras mutations in small cell lung cancer may be related to RB inactivation with loss of cyclin D1
The Ras oncoproteins is another cancer gene product that shows a curious relationship between tumors that can arise from cells with endocrine or non-endocrine differentiation. For example, while activating K-ras mutations are found in 90% of the non-endocrine (exocrine) adenocarcinomas of the pancreas and in a substantial subset of adenocarcinomas of the colon, lung, and thyroid, they are rarely detected in the endocrine tumors that arise from these same organs and may occur in 0% of medullary thyroid cancer and in 0% of neuroendocrine small cell lung cancer (Almoguera et al., 1988; Bockhorn et al., 2000; Capella et al., 1996; Mitsudomi et al., 1991) . Since activated Ras mutations require the presence of cyclin D1 to promote breast tumorigenesis , it is reasonable, therefore, to speculate that the absence of Ras mutations in small cell lung cancer may be directly linked to RB inactivation ( Figure 2) . As outlined previously, loss of RB function through mutational inactivation or through HPV infection (Kelley et al., 1995b) is associated with marked elevation of steady-state p16 levels. This induction of p16, in turn, can displace p27Kip family members from cdk4/6:cyclin D complexes resulting in loss of steady-state cyclin D1 levels. Interestingly, the resistance of cyclin D1 null murine breast tissues to the tumorigenic effects of neu over-expression, but not to the effects of ectopic Myc , also correlates with the absence of neu amplification Hirsch et al., 2002) , but the frequent over-expression of Myc in small cell lung cancer samples (Johnson et al., 1988) , It is possible to speculate that the absence of amplification of other related epidermal growth factor-like receptors in small cell lung cancer may also be related to absence of cyclin D1 in these tumors as well. This hypothesis, however, requires that RB alterations need to occur as the initial event in lung tumorigenesis. Studies on early dysplastic and carcinoma in situ samples confirm this sequential requirement and show that RB and p16 genetic or epigenetic alterations are very early events in lung cancer (Nuovo et al., 1999; Park et al., 1999; Zochbauer-Muller et al., 2002) , while Ras mutations develop later in the course of tumorigenesis (Sugio et al., 1994) .
Distinctions between RB and p16 loss
We have already discussed that approximately 10% of small cell lung cancer retain wildtype RB function and inactivate p16. This observation directly implies that loss of p16 (with concomitant constitutive hyperphosphorylation of RB) may be functionally equivalent to a null RB phenotype. According to the model presented in Figure 1 , however, there are substantial biochemical differences that could be predicted between these two genotypes. For example, an RB mutation will release and 'activate' the family of RB binding proteins and also induce p16 protein levels resulting in loss of steady-state levels of cyclin D1 and the induction of p27Kip-mediated suppression of CDK2:cyclin E. In contrast, the loss of p16 is predicted to disrupt the 'pocket' binding function of all members of the RB pocket family, including RB, p107, and p130 (Lipinski and Jacks, 1999; Nevins, 1998) . The role of p107 and p130 in lung cancer, however, is uncertain as only one small cell lung cancer cell line has been detected with a p130 alteration (Helin et al., 1997) and other studies have shown no alterations (Modi et al., 2000) . In addition, recent reports of p130 alterations in some cases of lung cancer (Claudio et al., 2000) , were subsequently interpreted as sequencing errors (Gray et al., 2001; Modi et al., 2000) . Despite the lack of p107 and p130 mutations in lung cancer samples, however, it is still plausible that the simultaneously inactivation all three pocket RB members, through loss of p16 function, could confer an enhanced proliferative signal as compared with RB alone (Classon et al., 2000; Zalvide et al., 1998) . As described above, the absence of p16 protein will also indirectly activate cyclin E (Jiang et al., 1998) to maximally phosphorylate RB and to deregulate, perhaps, other candidate substrate(s).
In summary, while there are substantial biochemical differences between RB and p16 loss, there is no explanation for the preferential mutational inactivation of RB in small cell lung cancer. Cell lineage specific differences in the ability to undergo DNA chromatin methylation/acetylation events might promote a stochastic preference to selectively target a specific locus for either genetic or epigenetic inactivation in different cell types that have been chronically exposed to the same carcinogen. Alternatively, a multipotent lung cancer progenitor cell target might differentiate along different cell lineage pathways depending on the expression patterns of different activated oncogenes/ tumor suppressor genes (Falco et al., 1990) . A more likely hypothesis, however, proposes that one pattern of sequential gene mutations either (i) stimulates cell proliferation or aberrant survival (positive selection) or (ii) induces cell death (negative selection) differentially in cell lineages committed to either neuroendocrine vs exocrine vs squamous differentiation. One would predict that the nature of the specific initial ratelimiting mutation would then lock the future tumor cell into a more-or-less predictable pattern of additional gene alteration events.
